NewLink Genetics

NLNK NASDAQ
1.400
-0.060
-4.11%
Opening 14:39 07/15 EDT
Open
1.460
Prev Close
1.460
High
1.470
Low
1.400
Volume
186.36K
Avg Vol (3M)
363.49K
52 Week High
4.860
52 Week Low
1.278
% Turnover
0.50%
Market Cap
52.19M
1D
5D
1M
3M
1Y
5Y

Related

Webull offers NewLink Genetics NLNK stock price, real time market quotes, professional analyst ratings, and in-depth charts, You can share investing ideas in community to communicate with others and learn trading skills.

Company Profile

NewLink Genetics Corporation is a clinical-stage immuno-oncology company focused on discovering, developing and commercializing immunotherapeutic products for the treatment of cancer. The Company's portfolio includes biologic and small-molecule immunotherapy product candidates for a range of oncology indications. Its biologic product candidates are based on its HyperAcute Cellular Immunotherapy technology, which is designed to stimulate the human immune system to attack cancer cells. Its additional HyperAcute Cellular Immunotherapy product candidates in clinical development include tergenpumatucel-L and dorgenmeltucel-L for patients with advanced lung cancer and melanoma, respectively. Additionally, it has two small-molecule product candidates in clinical development: GDC-0919 and indoximod. These product candidates are indoleamine-2, 3-dioxygenase (IDO) pathway inhibitors and focus on breaking the immune system's tolerance to cancer.
MORE >

Recently

Name
Price
%Change